|Title:||Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1|
|Abstract:||A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.|
|Inventor(s):||Berger; Joseph R. (Miami, FL)|
|Assignee:||Bio-Technology General Corporation (Iselin, NJ)|
|Patent Claim Types:|
see list of patent claims
|Use; Delivery; Dosage form;|
|Country||Document Number||Publication Date|
|WIPO (PCT)||9408590||Apr 28, 1994|
|United States||2002091155||Jul 11, 2002|
|United States||6090799||Jul 18, 2000|
|United States||2007254029||Nov 01, 2007|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639